brolucizumab

Details

Files
Generic Name:
brolucizumab
Project Status:
Complete
Therapeutic Area:
Diabetic macular edema
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Beovu
Project Line:
Reimbursement Review
Project Number:
SR0747-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
The treatment of diabetic macular edema (DME).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​The treatment of diabetic macular edema (DME).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input openJune 02, 2022
Call for patient/clinician input closedJuly 22, 2022
Clarification:

- Patient input submission received from Fighting Blindness Canada, The Canadian Council of the Blind, CNIB, Vision Loss Rehabilitation Canada, Diabetes Canada

Submission receivedJune 30, 2022
Submission acceptedJuly 15, 2022
Review initiatedJuly 18, 2022
Draft CADTH review report(s) provided to sponsor for commentOctober 06, 2022
Deadline for sponsors commentsOctober 18, 2022
CADTH review report(s) and responses to comments provided to sponsorNovember 11, 2022
Expert committee meeting (initial)November 23, 2022
Draft recommendation issued to sponsorDecember 07, 2022
Draft recommendation posted for stakeholder feedbackDecember 15, 2022
End of feedback periodJanuary 06, 2023
Final recommendation issued to sponsor and drug plansJanuary 18, 2023
Final recommendation postedFebruary 08, 2023
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)February 02, 2023
CADTH review report(s) postedMarch 29, 2023